1. Home
  2. ACRS
  3. ACRS News

Latest Aclaris Therapeutics Inc. (ACRS) News on February 23, 2025

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
ACRS

GlobeNewswire

11 days ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
ACRS

GlobeNewswire

23 days ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ACRS

GlobeNewswire

2 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ACRS

MT Newswires

2 months ago

HC Wainwright Upgrades Aclaris Therapeutics to Buy From Neutral, $20 Price Target

ACRS

MT Newswires

2 months ago

Aclaris Therapeutics Files Statement for Share Resale by Stockholders; Stock Rises After Hours

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ACRS

GlobeNewswire

3 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
ACRS

GlobeNewswire

3 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Therapeutics And 2 Other US Penny Stocks To Watch
ACRS

Simply Wall St.

3 months ago

Aclaris Therapeutics And 2 Other US Penny Stocks To Watch

ACRS

MT Newswires

3 months ago

Cantor Fitzgerald Upgrades Aclaris Therapeutics to Overweight

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies
ACRS

TipRanks

3 months ago

Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG
ACRS

TipRanks

3 months ago

Aclaris Therapeutics upgraded to Buy from Neutral at BTIG

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
ACRS

Benzinga

3 months ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

ACRS

MT Newswires

3 months ago

Aclaris Therapeutics Shares Soar After Multiple Analyst Upgrades

ACRS

MT Newswires

3 months ago

Top Midday Gainers

Aclaris Therapeutics secures global rights to Biosion’s antibodies
ACRS

Pharmaceutical Technology

3 months ago

Aclaris Therapeutics secures global rights to Biosion’s antibodies

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
ACRS

Zacks

3 months ago

ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs

ACRS

MT Newswires

3 months ago

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Price Target is $13

ACRS

MT Newswires

3 months ago

BTIG Upgrades Aclaris Therapeutics to Buy, Price Target is $8

ACRS

MT Newswires

3 months ago

Jefferies Upgrades Aclaris Therapeutics to Buy, Price Target is $7

ACRS

MT Newswires

3 months ago

Aclaris Therapeutics Signs License Agreement with Chinese Biotech Biosion

ACRS

MT Newswires

3 months ago

Aclaris Therapeutics Raises $80 Million Through Private Placement

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets
ACRS

PR Newswire

3 months ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
ACRS

GlobeNewswire

3 months ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement
ACRS

GlobeNewswire

3 months ago

Aclaris Therapeutics Announces $80 Million Private Placement

News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts
ACRS

Simply Wall St.

3 months ago

News Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Forecasts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
ACRS

Simply Wall St.

3 months ago

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
ACRS

Zacks

4 months ago

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates

ACRS

Associated Press Finance

4 months ago

Aclaris: Q3 Earnings Snapshot

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

4 months ago

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
ACRS

Simply Wall St.

4 months ago

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
ACRS

GuruFocus.com

4 months ago

Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
ACRS

Zacks

4 months ago

Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial
ACRS

Clinical Trials Arena

5 months ago

Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
ACRS

GlobeNewswire

5 months ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
ACRS

GlobeNewswire

5 months ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
ACRS

Simply Wall St.

6 months ago

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations
ACRS

Simply Wall St.

6 months ago

Aclaris Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
ACRS

Zacks

7 months ago

Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

7 months ago

Aclaris: Q2 Earnings Snapshot

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

7 months ago

Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?
ACRS

Simply Wall St.

7 months ago

Will Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS

Zacks

7 months ago

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

ACRS

MT Newswires

7 months ago

Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
ACRS

GlobeNewswire

7 months ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
ACRS

Zacks

7 months ago

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

ACRS

MT Newswires

8 months ago

Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing

ACRS

MT Newswires

8 months ago

Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
ACRS

GlobeNewswire

9 months ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
ACRS

Simply Wall St.

9 months ago

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
ACRS

Insider Monkey

9 months ago

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript

ACRS

Thomson Reuters StreetEvents

9 months ago

Q1 2024 Aclaris Therapeutics Inc Earnings Call

ACRS

GuruFocus.com

9 months ago

Aclaris Therapeutics Inc (ACRS) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates
ACRS

Zacks

10 months ago

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

10 months ago

Aclaris: Q1 Earnings Snapshot

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

10 months ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
ACRS

GlobeNewswire

10 months ago

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer
ACRS

PR Newswire

10 months ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock
ACRS

Simply Wall St.

10 months ago

Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
ACRS

Zacks

a year ago

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?
ACRS

Zacks

a year ago

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Aclaris (ACRS) Upgraded to Buy: Here's Why
ACRS

Zacks

a year ago

Aclaris (ACRS) Upgraded to Buy: Here's Why

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
ACRS

Zacks

a year ago

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations
ACRS

Simply Wall St.

a year ago

Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations

Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%
ACRS

Simply Wall St.

a year ago

Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
ACRS

Zacks

a year ago

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

ACRS

Associated Press Finance

a year ago

Aclaris: Q4 Earnings Snapshot

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Can Aclaris Therapeutics (NASDAQ:ACRS) Afford To Invest In Growth?
ACRS

Simply Wall St.

a year ago

Can Aclaris Therapeutics (NASDAQ:ACRS) Afford To Invest In Growth?

Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release
ACRS

Zacks

a year ago

Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know
ACRS

Zacks

a year ago

Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
ACRS

Zacks

a year ago

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

ACRS

Associated Press Finance

a year ago

Investar: Q4 Earnings Snapshot

Investar Holding Corporation Announces 2023 Fourth Quarter Results
ACRS

ACCESSWIRE

a year ago

Investar Holding Corporation Announces 2023 Fourth Quarter Results

PodcastOne Renews Agreement with The Adam Carolla Podcast and The Adam and Dr. Drew Show
ACRS

GlobeNewswire

a year ago

PodcastOne Renews Agreement with The Adam Carolla Podcast and The Adam and Dr. Drew Show

InTest Corporation (INTT) Surpasses Market Returns: Some Facts Worth Knowing
ACRS

Zacks

a year ago

InTest Corporation (INTT) Surpasses Market Returns: Some Facts Worth Knowing

Byrna Technologies Partners with Leading Multi-Media Personality Glenn Beck
ACRS

PR Newswire

a year ago

Byrna Technologies Partners with Leading Multi-Media Personality Glenn Beck

ACRS

Zacks Small Cap Research

a year ago

AIXI: Initiating Coverage – The AI hype cycle subsides but opportunities and challenges lie ahead in 2024

Hot Stocks Roundup: Why Are People Talking About WW International and Zoom Video Communications Stocks Right Now?
ACRS

Motley Fool

a year ago

Hot Stocks Roundup: Why Are People Talking About WW International and Zoom Video Communications Stocks Right Now?

LivePerson, Inc.'s (NASDAQ:LPSN) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
ACRS

Simply Wall St.

a year ago

LivePerson, Inc.'s (NASDAQ:LPSN) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

AstroNova Updates Upcoming Investor Conference Schedule
ACRS

Business Wire

a year ago

AstroNova Updates Upcoming Investor Conference Schedule

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
ACRS

Zacks

a year ago

Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO

Why the Market Dipped But inTest Corporation (INTT) Gained Today
ACRS

Zacks

a year ago

Why the Market Dipped But inTest Corporation (INTT) Gained Today

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024
ACRS

PR Newswire

a year ago

Accuray to Report Second Quarter Fiscal 2024 Financial Results on January 31, 2024

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

LuxUrban Hotels Announces that The Royalton by LuxUrban, Trademark Collection® by Wyndham Will Begin Welcoming Guests in January
ACRS

Business Wire

a year ago

LuxUrban Hotels Announces that The Royalton by LuxUrban, Trademark Collection® by Wyndham Will Begin Welcoming Guests in January

Kings River Packing Becomes First in Citrus to Implement Traceability
ACRS

Business Wire

a year ago

Kings River Packing Becomes First in Citrus to Implement Traceability

A Look Back at General Merchandise Retail Stocks' Q3 Earnings: Big Lots (NYSE:BIG) Vs The Rest Of The Pack
ACRS

StockStory

a year ago

A Look Back at General Merchandise Retail Stocks' Q3 Earnings: Big Lots (NYSE:BIG) Vs The Rest Of The Pack

LuxUrban Hotels to Present at Upcoming Investor Conferences
ACRS

Business Wire

a year ago

LuxUrban Hotels to Present at Upcoming Investor Conferences

Everspin Technologies Announces Participation in 26th Annual Needham Growth Conference
ACRS

Business Wire

a year ago

Everspin Technologies Announces Participation in 26th Annual Needham Growth Conference

CI&T Releases 2024 Connected Retail Report
ACRS

Business Wire

a year ago

CI&T Releases 2024 Connected Retail Report

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Xiao-I and eRoad Forge Strategic Partnership to Drive Commercialization Through Xiao-I's Hua Zang Ecosystem
ACRS

ACCESSWIRE

a year ago

Xiao-I and eRoad Forge Strategic Partnership to Drive Commercialization Through Xiao-I's Hua Zang Ecosystem

Investors in Virco Mfg (NASDAQ:VIRC) have seen enviable returns of 413% over the past three years
ACRS

Simply Wall St.

a year ago

Investors in Virco Mfg (NASDAQ:VIRC) have seen enviable returns of 413% over the past three years

Focus Universal to Showcase Innovative IoT Solutions at CES 2024
ACRS

ACCESSWIRE

a year ago

Focus Universal to Showcase Innovative IoT Solutions at CES 2024

Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk
ACRS

Zacks

a year ago

Omega (OMGA) Up 95% on Obesity Drug Deal With Novo Nordisk

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
ACRS

Zacks

a year ago

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

CTO Realty Growth Announces Sale of Single Tenant Office Property in Tampa, FL For $22.0 Million
ACRS

GlobeNewswire

a year ago

CTO Realty Growth Announces Sale of Single Tenant Office Property in Tampa, FL For $22.0 Million

Zapata AI Research in Quantum-Enhanced Generative AI Published in Nature Communications
ACRS

Business Wire

a year ago

Zapata AI Research in Quantum-Enhanced Generative AI Published in Nature Communications

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
ACRS

Simply Wall St.

a year ago

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone

Aclaris Therapeutics Provides Corporate Update
ACRS

GlobeNewswire

a year ago

Aclaris Therapeutics Provides Corporate Update

Share on Social Networks: